Favorable mid-term performance of fully biodegradable implantable device for ventricular septal defect closureCentral MessagePerspective

Objectives: To assess the mid-term safety and efficacy of transthoracic perimembranous ventricular septal defect (Pm-VSD) closure using a new biodegradable device. Implantation entailed right subaxillary minithoracotomy under transesophageal echocardiography guidance. Methods: Between October 2019 a...

Full description

Saved in:
Bibliographic Details
Main Authors: Shubo Song, MD, Zehua Shao, MD, Taibing Fan, Prof, Bin Li, MD, Weijie Liang, MD, Haoju Dong, MD, Kaiyuan Wu, MD, Manman Hu, MD, Yu Han, MD, Cunying Cui, MD
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:JTCVS Techniques
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666250722005909
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To assess the mid-term safety and efficacy of transthoracic perimembranous ventricular septal defect (Pm-VSD) closure using a new biodegradable device. Implantation entailed right subaxillary minithoracotomy under transesophageal echocardiography guidance. Methods: Between October 2019 and January 2020, 13 patients (males, 5; mean age, 3.6 ± 2.5 years) with Pm-VSDs underwent transthoracic device closures at Zhengzhou University Central China Fuwai Hospital as described previously. Delivery pathways were established by manipulating a hollow probe from right atrium through tricuspid valve to right ventricle and then through VSDs to left ventricle, whereupon installation took place. Results: All occluder implantations were successfully executed. Mean defect size was 4.1 ± 1.0 mm, and mean device waist size was 5.2 ± 1.1 mm. One patient (7.7%) with 1.5-mm residual shunt showed complete closure at discharge. There was 1 instance of postoperative incomplete right bundle branch block, which converted to complete right bundle branch block at month 1. During patient follow-up (mean, 24.6 ± 0.8 months), no device dislocations, new residual shunts, new valvular regurgitation, or detectable atrioventricular block ensued. Conclusions: Closure of Pm-VSDs using a novel, fully biodegradable occluder in the manner described has proven safe and effective at mid-term follow-up. Long-term safety and efficacy of this device must be further corroborated in a large patient cohort going forward.
ISSN:2666-2507